DOI: 10.4244/EIJV12SYA28

Percutaneous interventional options for the treatment of tricuspid regurgitation

Michael Haude1*, MD, PhD; Bernard Prendergast2, DM, FRCP, FESC

Tricuspid regurgitation (TR) can be differentiated as primary (mainly due to infective endocarditis), as secondary or functional (due to annular dilatation and leaflet tethering as a consequence of right ventricular dilatation and remodelling). Although functional TR is broadly underdiagnosed, it is associated with symptoms of right heart failure, reduced quality of life and poor outcome. As a stand-alone therapy, surgical repair for functional TR is rarely performed because it is associated with poor outcome owing to patient comorbidities. Moreover, although concomitant surgical tricuspid valve repair is frequently considered in patients with functional TR who require surgical repair of other valves and/or bypass surgery, many are poor candidates for surgery on account of their prohibitive risk profiles. Therefore, novel transcatheter therapies have been developed in recent years to address the needs of patients with significant functional TR. This chapter of the EuroIntervention London Valves supplement summarises four currently available percutaneous catheter-based repair techniques and a fifth option of heterotopic valve implantation.

Rosser et al present the TriCinch™ (4Tech Cardio Ltd, Galway, Ireland) system, a transfemoral venous access device designed for tricuspid valve remodelling to reduce annular dilatation and prevent further right heart decompensation. The TriCinch™ system has two components: A) a stainless steel corkscrew implant, which is placed in the anterior annulus of the tricuspid valve in close proximity to the anteroposterior commissure, and B) a self-expanding nitinol stent that is deployed below the hepatic region of the inferior vena cava. Under transoesophageal echocardiographic and fluoroscopic guidance, the system allows gradual tension on the tricuspid annulus with reduction of annular dimensions and TR.

Puri et al describe the FORMA repair system (Edwards Lifesciences, Irvine, CA, USA), which consists of a foam-filled polymer balloon spacer advanced via the subclavian vein, positioned across the tricuspid valve and fixed at the right ventricular apex. Positioning of the spacer across the tricuspid valve reduces the regurgitant space and associated functional TR.

Schofer presents the Trialign device (Mitralign, Inc., Boston, MA, USA), which consists of three main components: A) an 8 Fr articulating catheter for wire delivery, B) a pledget catheter preloaded with the ventricular and atrial components of the pledget (size 4×8 mm), and C) a plication lock device used to perform the cinching, lock the sutures and maintain pledget position. After placing two pledgets in the annulus under transoesophageal echocardiographic guidance, a dedicated plication lock device fixes the plication to create a tricuspid annuloraphy.

Schüler et al describe use of the MitraClip® device (Abbott Vascular, Santa Clara, CA, USA), which is primarily indicated for the percutaneous treatment of primary or secondary mitral regurgitation but has also been recently used in small numbers of patients for the treatment of primary or functional TR.

Finally, Figulla et al present the concept of heterotopic placement of catheter-based valves into the inferior and superior vena cava for treatment of TR. The TricValve (P&F Company, Weßling, Germany) consists of two different self-expandable pericardial tissue valve designs on nitinol stent frames intended for implantation in the inferior or superior vena cava.

Each of these approaches is at an early stage of development with good results in highly selected patients. Numerous other innovative tricuspid devices are under investigation in preclinical models and this area of percutaneous valve intervention is set for considerable progress in the near future.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 12 Supplement Y
Sep 18, 2016
Volume 12 Supplement Y
View full issue


Key metrics

On the same subject

10.4244/EIJV11SWA37 Sep 17, 2015
Tricuspid valve interventions in 2015
Lauten A and Figulla HR
free

10.4244/EIJV15I10A159 Nov 15, 2019
The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why
Williams A et al
free

TRICUSPID VALVE INTERVENTIONS

10.4244/EIJV12SYA30 Sep 18, 2016
Transcatheter interventions for tricuspid regurgitation: TriCinch (4Tech)
Rosser B et al
free

EXPERT REVIEW

10.4244/EIJ-D-17_00487 Sep 24, 2017
Transcatheter tricuspid valve intervention: state of the art
Taramasso M and Maisano F
free

10.4244/EIJV12I15A292 Feb 3, 2017
The forgotten valve no more
Mylotte D
free

TRICUSPID VALVE INTERVENTIONS

10.4244/EIJV12SYA29 Sep 18, 2016
Transcatheter interventions for tricuspid regurgitation: MitraClip
Schueler R et al
free

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00571 Sep 24, 2017
The big parade: emerging percutaneous mitral and tricuspid valve devices
Natarajan D et al
free
Trending articles
281.88

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved